RBC Capital Maintains Outperform on BeOne Medicines, Raises Price Target to $465

Benzinga · 1d ago
RBC Capital analyst Leonid Timashev maintains BeOne Medicines (NASDAQ:ONC) with a Outperform and raises the price target from $459 to $465.